Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy

Abstract Blocking PD-1/PD-L1 interaction shows remarkable antitumor efficacy clinically but systemic administration can cause immune-related adverse events in multiple organs from nonspecific T-cell activation, restricting the clinical safety window. Achieving spatiotemporal regulation of immune checkpoint blockadepreserving antitumor immunity while avoiding systemic toxicityis a key challenge. Prodrug strategies, particularly photocaging, enable on-demand light-triggered drug activation. Here, we propose a prodrug design for small-molecule PD-L1 inhibitors using coumarin photocaging groups. Guided by cocrystal binding mode analysis, we covalently masked two inhibitors with coumarin photolabile protecting groups, and designed and synthesized the corresponding photocaged prodrugs. In vitro, the prodrugs were inactive under dark conditions, but upon visible light activation, they restored T-cell effector function and restored T-cell effector function in PD-L1-dependent co-culture models. These results validate the on-demand release pharmacological property, providing a feasible approach for spatiotemporally controllable immunotherapy in superficial or optically accessible lesions.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-14
DOI
https://doi.org/10.1021/acs.jmedchem.6c02082
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy

Peng Yang, Lili Zhu, Hong Wang, Binjian Jiang et al.
Journal of Medicinal Chemistry
Cancer Immunotherapy and Biomarkers
article

Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy

Peng Yang, Lili Zhu, Hong Wang, Binjian Jiang, Chengliang Sun, Danfeng Wang, Yibei Xiao, Pan Yang, Lili Wang, Liping Wang, Guangqi Xia
article en

Abstract

Abstract Blocking PD-1/PD-L1 interaction shows remarkable antitumor efficacy clinically but systemic administration can cause immune-related adverse events in multiple organs from nonspecific T-cell activation, restricting the clinical safety window. Achieving spatiotemporal regulation of immune checkpoint blockadepreserving antitumor immunity while avoiding systemic toxicityis a key challenge. Prodrug strategies, particularly photocaging, enable on-demand light-triggered drug activation. Here, we propose a prodrug design for small-molecule PD-L1 inhibitors using coumarin photocaging groups. Guided by cocrystal binding mode analysis, we covalently masked two inhibitors with coumarin photolabile protecting groups, and designed and synthesized the corresponding photocaged prodrugs. In vitro, the prodrugs were inactive under dark conditions, but upon visible light activation, they restored T-cell effector function and restored T-cell effector function in PD-L1-dependent co-culture models. These results validate the on-demand release pharmacological property, providing a feasible approach for spatiotemporally controllable immunotherapy in superficial or optically accessible lesions.

Journal of Medicinal Chemistry
China Pharmaceutical University (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon